Unfortunately, the combination of PARP inhibitors with cyclophosphamide does not improve response rate over cyclophosphamide alone, at least in the setting of breast cancer, and combinations with lomustine are understudied (55). This evidence concerns the gene PARP1 and breast carcinoma.